- Current report filing (8-K)
March 12 2010 - 5:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of report
:
March 12, 2010
(Date of
earliest event reported)
AFFYMETRIX,
INC.
(Exact
name of registrant as specified in charter)
Delaware
|
|
0-28218
|
|
77-0319159
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
3420
Central Expressway
Santa
Clara, California 95051
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (
408) 731-5000
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Affymetrix,
Inc. (the “Company”) announced that Timothy C. Barabe will join the Company as
Executive Vice President and Chief Financial Officer effective
March 15, 2010. Mr. Barabe
will replace
John C. Batty, who will depart the Company on
March 15, 2010. The Company expects to enter into a separation
agreement with Mr. Batty relating to his separation from
employment.
Mr. Barabe, aged 56, previously worked
at Human Genome Sciences, Inc. where he served as Senior Vice President and
Chief Financial Officer since July of 2006. From September 2004 to June 2006,
Mr. Barabe was at Molnlycke Health Care, a privately owned surgical supply
company, most recently as its U.K. Managing Director. Mr. Barabe
was with Novartis AG from 1982 to 2004 in several senior executive
positions. Mr. Barabe is a member of the Board of Directors of
ArQule, Inc.
Pursuant to Mr. Barabe’s at-will offer
letter, he will receive an annual base salary of $380,000 and will be eligible
to receive an annual bonus at a target level equal to 50% of his base salary,
with actual payment based on the terms of the Company’s performance bonus
program. In addition, the Company will grant Mr. Barabe options to
purchase 90,000 shares of common stock, at an exercise price equal to the fair
market value of the shares on the grant date, and 20,000 restricted shares of
common stock, which awards will both vest over four years. Mr. Barabe
is also entitled to reimbursement of certain relocation
expenses.
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, hereunto duly
authorized.
|
AFFYMETRIX,
INC.
|
|
|
|
|
|
|
|
Date:
March 12, 2010
|
By:
|
/s/
John F. Runkel, Jr.
|
|
|
|
John
F. Runkel, Jr.
|
|
|
|
Executive
Vice President, General Counsel
and
Secretary
|
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024